| Latest Sanofi-Aventis News Headlines |
| Date | Time | Source | |
| 11/19/2009 | 8:30AM | PRNUS | New GoMeals(TM) iPhone Application from sanofi-aventis U.S. to Help People with Diabetes Eat Healthy Anywhere, Anytime
BRIDGEWATER, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced today that GoMeals(TM), a new iPhone application (app) designed to help people living with diabetes make healthy food choices, is now available for download at the iTunes App store. GoMeals(TM) is a food tracking tool which allows users... More...>> |
| 11/11/2009 | 2:00PM | PRNUS | Video: Sanofi Pasteur Announces Final Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Adults and Children
- Final data confirm immunogenicity, safety profile - - Single dose provides robust immune response in adults; two doses provide robust immune response in children 6 months through 9 years -
SWIFTWATER, Pa., Nov. 11 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE:... More...>> |
| 11/10/2009 | 4:30PM | PRNUS | Sanofi-aventis and Regeneron Expand Strategic Antibody Collaboration
- New agreements expand and extend November 2007 antibody collaboration - Collaboration goal is to advance 4 to 5 antibodies per year into clinical development - Sanofi-aventis to fund up to $160M annually for Regeneron antibody discovery research until end of 2017
PARIS, and TARRYTOWN, N.Y., Nov. 10 /PRNewswire-FirstCall/... More...>> |
| 11/02/2009 | 8:00AM | PRNUS | Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
The two-dose meningococcal quadrivalent conjugate vaccine was generally well-tolerated
PHILADELPHIA, Nov. 2 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), presented Safety of a Quadrivalent (A,C,Y,W-135) Meningococcal Vaccine When Given to Infants with Other... More...>> |
| 10/30/2009 | 8:13AM | PRNUS | Sanofi-aventis Delivers a Solid Performance in Third Quarter 2009
BRIDGEWATER, N.J., Oct. 30 /PRNewswire-FirstCall/ --
2009 Q3 Change Change at 2009 Change Change at
on a constant 9 months on a constant
reported exchange reported exchange
basis... More...>> |
| 10/20/2009 | 9:16AM | PRNUS | Weekly Digest's Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 'Swine Flu' Outbreak
PRINCETON, N.J., Oct. 20 /PRNewswire/ -- Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for GlaxoSmithKline (NYSE:GSK), Sanofi-Aventis... More...>> |
| 10/16/2009 | 5:31PM | PRNUS | FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumo
- Elitek is now approved to manage a potentially life-threatening complication associated with anti-cancer treatment in adults -
BRIDGEWATER, N.J., Oct. 16 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Elitek® (rasburicase... More...>> |
| 10/14/2009 | 9:01AM | PRNUS | Sanofi Pasteur Announces Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Infants and Children
- The first clinical trial data from America's youngest vaccine recipients, children 6 months through 9 years of age, show the vaccine induces an immune response and is well-tolerated - - Data indicate that two doses of vaccine will be required for optimum protection of children under the age of 10 years -
SWIFTWATER... More...>> |
| 10/05/2009 | 3:41PM | PRNUS | National Transitions of Care Coalition Releases Health Care Tools in Spanish and French
LITTLE ROCK, Ark., Oct. 5 /PRNewswire/ -- Today, the National Transitions of Care Coalition (NTOCC) released Spanish and French translations of patient/caregiver tools, Taking Care of MY Health Care and My Medicine List. The tools, originally developed in English, provide a resource which patients and their caregivers... More...>> |
| 10/01/2009 | 12:08PM | PRNUS | Sanofi Pasteur Announces Results of U.S. Clinical Trials in Adults Following One Dose of Influenza A (H1N1) Vaccine
- Data from studies in adults 18 years of age and older provide confirmation that one dose of vaccine produces a robust immune response even in those over the age of 65 years -
LYON, France and SWIFTWATER, Pa., Oct. 1 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and... More...>> |
| 10/01/2009 | 7:00AM | PRNUS | Sanofi-aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM-121, an Anti-Erb
Merrimack eligible to receive up to $530 million, comprised of $60 million upfront plus milestone payments, in addition to future royalties. Merrimack will lead MM-121 development through proof of concept and retains the right to co-promote in the United States
CAMBRIDGE, Mass., Oct. 1 /PRNewswire/ -- Merrimack Pharmaceuticals... More...>> |
| 09/30/2009 | 2:30AM | PRNUS | Superior Efficacy-dose Ratio for Lantus(R) Over detemir
PARIS, September 30 /PRNewswire-FirstCall/ -- - 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R)
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour... More...>> |
| 09/28/2009 | 2:00AM | PRNUS | Sanofi Aventis : Multaq(R) (dronedarone) Recommended for Approval in the European Union
PARIS, September 28 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R... More...>> |
| 09/25/2009 | 12:15PM | PRNUS | Sanofi Aventis : Multaq(R) (dronedarone) Recommended for Approval in the European Union
PARIS, September 25 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R... More...>> |
| 09/24/2009 | 9:31AM | PRNUS | Critical Alerts for Palm, NetApp, United Technologies, Expedia and Sanofi Aventis
CHICAGO, Sept. 24 /PRNewswire/ -- Seven Summits Research issues PriceWatch Alerts for PALM, NTAP, UTX, EXPE and SNY.
Seven Summits Strategic Investments' PriceWatch Alerts are available at http://www.iotogo.com/s/092409A (Note: You may have to copy this link into your browser then press the [ENTER] key.)
Today's PriceWatch... More...>> |
| 09/16/2009 | 4:45PM | PRNUS | Sanofi-Aventis Receives Complete Response Letter from the FDA for Eplivanserin (Ciltyri(R)) Submission
BRIDGEWATER, N.J., Sept. 16 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the company's New Drug Application (NDA) for eplivanserin (Ciltyri ). Eplivanserin was reviewed as a potential... More...>> |
| 09/15/2009 | 3:22PM | PRNUS | U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine
- Influenza A (H1N1) 2009 Monovalent Vaccine licensure a key U.S. milestone in preparing for pandemic response this Fall -
LYON, France and SWIFTWATER, Pa., Sept. 15 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and... More...>> |
| 09/08/2009 | 9:00AM | PRNUS | VIDEO: Nasal Allergy Experts Offer Free Advice for Back to School Sneezin'
New Tips from the Xperts on How to Help Children Manage Nasal Allergies In and Out of the Classroom
ATLANTA and BRIDGEWATER, N.J. Sept. 8 /PRNewswire/ -- From cubbies and carpets to class pets and pollen, as parents prepare for this year's back to school they should also prepare for the upcoming fall allergy season... More...>> |
| 08/31/2009 | 4:35AM | PRNUS | Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
PARIS, August 31 /PRNewswire-FirstCall/ -- - SEPIA-ACS Multiple-Dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet -
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational... More...>> |
| 08/30/2009 | 6:12AM | PRNUS | Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
PARIS, August 30 /PRNewswire-FirstCall/ -- - SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational... More...>> |